awmsg logo



telotristat ethyl (Xermelo®)


Reference No. 2037

Publication date:
25/07/2018


Appraisal information

telotristat ethyl (Xermelo®) 250 mg film-coated tablet


Company: Ipsen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 13/06/2018
AWMSG meeting date: 18/07/2018
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1018
Ratification by Welsh Government: 23/07/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Telotristat ethyl (Xermelo®) is recommended as an option for restricted use within NHS Wales. Telotristat ethyl (Xermelo®) is licensed for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. Telotristat ethyl (Xermelo®) is restricted for use for the treatment of carcinoid syndrome diarrhoea in adults who are inadequately controlled by SSA therapy and who experience an average of four or more bowel movements a day. Telotristat ethyl (Xermelo®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download